Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19954523 | 0.92 | TGFBR1 (0.35) | MEN1KMT2ATGFBR1MAP3K12NR3C2 | |
| SCHEMBL19105611 | 0.87 | TGFBR1 (0.35) | LMNAMEN1KMT2ATGFBR1MAP3K12 | |
| SCHEMBL19954552 | 0.86 | MAP3K12 (0.33) | TGFBR1MAP3K12NR3C2KCNN4 | |
| SCHEMBL19954611 | 0.84 | MPO (0.35) | MEN1KMT2ATGFBR1MAP3K12NR3C2 | |
| SCHEMBL18164113 | 0.82 | GAA (0.38) | LMNACYP2C9MEN1KMT2ATGFBR1 | |
| SCHEMBL19954663 | 0.81 | NR3C2 (0.38) | MEN1KMT2ATGFBR1MAP3K12NR3C2 | |
| SCHEMBL19954553 | 0.81 | NR3C2 (0.40) | MEN1KMT2ATGFBR1MAP3K12NR3C2 | |
| SCHEMBL21023784 | 0.81 | NR3C2 (0.36) | LMNATGFBR1MAP3K12NR3C2 | |
| SCHEMBL19954571 | 0.81 | NR3C2 (0.34) | TGFBR1MAP3K12NR3C2 | |
| SCHEMBL19954547 | 0.80 | MEN1 (0.40) | MEN1KMT2ANR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392350-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3080087-B1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20180222867-A1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION | 2018-08-09 | — | — | US | disclosed |
| US-9914706-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392350-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | ATP5F1A, ATP5ME, ATP5F1D | LMNA 3599/4885CYP2C9 2358/4885MEN1 3723/4885 |
| US-20180222867-A1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | LMNA 3599/4885CYP2C9 2358/4885MEN1 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.